Paola Antonelli
#16,123
Most Influential Person Now
Italian architect, curator, author, and educator
Paola Antonelli's AcademicInfluence.com Rankings
Paola Antonelliengineering Degrees
Engineering
#464
World Rank
#787
Historical Rank
Architecture
#162
World Rank
#382
Historical Rank
Applied Physics
#3863
World Rank
#4030
Historical Rank
Download Badge
Engineering Communications
Paola Antonelli's Degrees
- Masters Architecture Polytechnic University of Milan
Why Is Paola Antonelli Influential?
(Suggest an Edit or Addition)According to Wikipedia, Paola Antonelli is an Italian architect, curator, author, editor, and educator. Antonelli is the Senior Curator of Architecture and Design at the Museum of Modern Art , New York, where she also serves as the founding Director of Research and Development. She has been described as "one of the 25 most incisive design visionaries in the world" by TIME magazine.
Paola Antonelli's Published Works
Published Works
- Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (2005) (83)
- Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never‐Smokers and EGFR‐Mutant Patients (2018) (71)
- Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. (2018) (69)
- Clustering of ALS patients in central Italy due to the occurrence of the L84F SOD1 gene mutation (1999) (49)
- Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. (2019) (34)
- EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect. (2016) (28)
- Q Fever in Como, Northern Italy (2004) (24)
- Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. (2019) (11)
- Alport syndrome: HLA association and kidney graft outcome. (2004) (6)
- Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population. (2016) (6)
- PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC). (2011) (6)
- Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer (2020) (5)
- Varicella in immunocompetent children in the first two years of life: role of treatment with oral acyclovir. Italian Acyclovir-Chickenpox Study Group. (1995) (5)
- Efficacy and safety of nivolumab in elderly patients (pts) with advanced squamous non small cell lung cancer (Sq-NSCLC) participating in the expanded access programme (EAP) in Italy (2016) (4)
- P1.06-006 Treatment beyond Progression in Patients with Advanced Squamous NSCLC Participating in the Expanded Access Programme (EAP): Topic: Advanced General (2017) (4)
- Increase of serum copper concentration in Löfgren syndrome. (1995) (3)
- 1318PItalian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients (2017) (2)
- A Nutritional Approach for the Management of Chemotherapy-Induced Diarrhea in Patients with Colorectal Cancer (2022) (2)
- Small Cell Lung Cancer (SCLC) in the left lung treated with chemotherapy and radiotherapy followed, after 5 years, by non-small lung cancer in the other lung (1994) (1)
- P3.02c-096 Use of Nivolumab in Elderly Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP): Topic: IT Clinical (2017) (1)
- A01*Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population (2016) (1)
- P-561 Lenograstim improves feasibility and activity of full dose (FD) chemotherapy in elderly SCLC patients: Final results of a phase II randomized Italian intergroup study (2003) (0)
- Correction Vol. 9, No. 6 (2004) (0)
- MA 11.11 Italian Nivolumab Expanded Access Program in Non-Squamous NSCLC Patients: Results in Never Smokers and EGFR Positive Patients (2017) (0)
- Correction Vol. 9, No. 11 (2004) (0)
This paper list is powered by the following services:
Other Resources About Paola Antonelli
What Schools Are Affiliated With Paola Antonelli?
Paola Antonelli is affiliated with the following schools: